Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 31, 2018. The document serves as a transaction notification regarding dealings in the company's ordinary shares by a Person Closely Associated (PCA) with a Principal Disclosing Manager (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Sale of Ordinary Shares |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Date | July 31, 2018 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details two separate sales of shares by Ms. R Redfern, a PCA of Mr. D Redfern (Chief Strategy Officer), on the same date:
- Transaction 1: Sale of 1,925 shares at a price of £15.75 per share.
- Transaction 2: Sale of 2,005 shares at a price of £15.75 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory notification of insider-related trading activity.
Key Facts for Investor Verification
- The transactions were executed by Ms. R Redfern, identified as a Person Closely Associated with the Chief Strategy Officer.
- Total volume sold in this notification was 3,930 ordinary shares.
- The execution price was consistent across both transactions at £15.75 per share.
- The filing does not disclose the total shareholding balance of the PCA or the PDMR following these sales.